Abstract: This study investigated the effects of single nucleotide polymorphisms (SNPs) in xenobiotic and steroid hormonemetabolizing genes in relation to breast cancer risk and explored possible effect modifications on persistent organic pollutants (POPs) and breast cancer associations. The study also assessed effects of Greenlandic BRCA1 founder mutations. Greenlandic Inuit women (77 cases and 84 controls) were included. We determined two founder mutations in BRCA1: Cys39Gly (rs80357164) and 4684delCC, and five SNPs in xenobiotic and oestrogen-metabolizing genes: CYP17A1 -34T>C (rs743572), CYP19A1 *19C>T (rs10046), CYP1A1 Ile462Val (rs1048943), CYP1B Leu432Val (rs1056836) and COMT Val158Met (rs4680). We used chi-square test for comparison of categorical variables between groups. Odds ratio (OR) estimates with 95% confidence interval (95%CI) were obtained using logistic regression models. The variant allele of BRCA1 Cys39Gly increased breast cancer risk (Gly/Cys versus Cys/Cys, OR: 12.2, 95%CI: 1.53; 98.1), and carriers of the variant allele of CYP17A1 -34T>C had reduced risk (CT+CC versus TT, OR: 0.44, 95%CI: 0.21; 0.93). CYP17A1 -34T>C was an effect modifier on the association between perfluoroalkyl acids (PFAAs) and breast cancer risk (∑PFAA, ratio of OR: 0.18, 95%CI: 0.03; 0.97). Non-significant modifying tendencies were seen for the other SNPs on the effect of polychlorinated biphenyls, organochlorine pesticides and PFAAs. In summary, the BRCA1 Cys39Gly and CYP17A1 -34T>C genetic variations were associated with breast cancer risk. Our results indicate that the evaluated genetic variants modify the effects of POP exposure on breast cancer risk; however, further studies are needed to document the data from the relatively small sample size.
Several genetic risk factors in breast cancer have been established; however, together with other known risk factors, they only explain a fraction of all breast cancer cases [1] . Variations in high-penetrance susceptibility genes such as the two best-known breast cancer risk genes, BRCA1 and BRCA2, only account for 5-15% of all familial breast cancer cases [2] . The allele frequencies of these genes are low in the general population, but women carrying a variation in one of the two genes have a 60-80% life-time risk of developing breast cancer [2] . A list of BRCA1 and BRCA2 founder mutations occurring in geographically, culturally or religiously isolated populations has been reported [3] , including two Greenlandic BRCA1 founder mutations with potential carcinogenic effects [4, 5] .
In addition to the high-penetrance risk genes, a range of lowpenetrance risk alleles/genes has been identified in relation to breast cancer [6] . As prolonged oestrogen exposure is the most established risk factor for breast cancer, genes involved in the synthesis and metabolism of steroids have attracted special interest. A number of genes in the cytochrome P450 (CYP) superfamily are involved in the synthesis and metabolism of oestrogens, and single nucleotide polymorphisms (SNPs) in the genes may alter the expression and activity of the enzymes [7] . CYP11A1, CYP17A1 and CYP19A1 are involved in synthesis of oestradiol from cholesterol ( fig. 1 ). Several SNPs in these genes together with SNPs in CYP1A1, CYP1A2, CYP1B1, CYP3A4 and COMT, being involved in the further metabolism, have been evaluated for their association with breast cancer [8] [9] [10] [11] . However, the results are inconclusive due to differences in study population, heterogeneous breast cancer aetiology and small sample sizes.
Some of the CYP genes are responsible for oxidative metabolism of numerous drugs and environmental chemicals, in addition to metabolism of oestrogen [12] . Interactions between SNPs in the CYP enzymes and several exposures were studied in relation to breast cancer risk, including exposures such as hormone replacement therapy [13] [14] [15] , ingestion of grilled/ smoked meat [16] and exposure to persistent organic pollutants (POPs) [9, 10, 17] . Several studies have reported an effect modification of Ile462Val in CYP1A1 on the association between polychlorinated biphenyls (PCBs) and breast cancer risk [17] [18] [19] [20] , even though the association between breast cancer and these two factors independently is inconsistent [21] [22] [23] [24] . An increase in risk may be driven by increased gene expression and enzyme activity of CYP1A1, leading to production of free radicals and oxidative DNA damage. Several other SNPs may also modify the effects of environmental exposures.
The aim of this study was to evaluate two Greenlandic BRCA1 founder mutations and selected SNPs in CYP17A1, CYP19A1, CYP1A1, CYP1B1 and COMT in relation to breast cancer risk. Furthermore, to explore whether the SNPs modified the effect of POPs levels on breast cancer risk.
For this study population, we previously reported associations between POPs [PCBs, perfluoroalkyl acids (PFAAs) and organochlorine pesticides (OCPs)] and breast cancer risk [25] . However, these associations may be heterogeneous between different genotypes of genetic variations.
Materials and Methods
Study population. Greenlandic Inuit women were recruited during 2000-2003 and 2011-2014 ; a detailed description of the study population has been reported previously [25] . A total of 77 cases and 84 controls were included from two sampling periods, 2000-2003 (31 cases and 31 controls) and 2011-2014 (46 cases and 53 controls). Breast cancer cases were recruited at Dronning Ingrid's Hospital in Nuuk, Greenland, and breast cancer diagnoses were histologically confirmed.
The controls recruited during 2000-2003 were selected from two cross-sectional studies on healthy persons [26, 27] . The controls included from Cote et al. [26] were all from Nuuk, and controls from Deutch et al. [27] were geographically more spread out and included to ensure that the controls were representative for the population of cases. The controls recruited during 2011-2014 were patients with non-malignant diagnoses at Dronning Ingrid's Hospital, Nuuk [28] . Fig. 1 . Cytochrome P450-mediated metabolic pathways of oestradiol and single nucleotide polymorphisms information. CYP11A1, CYP17A1, CYP19A1 and 17b-hydroxysteroid dehydrogenase (17b-HSD) convert cholesterol to oestradiol through several steps. Oestrogen is transformed into 2-hydroxyoestradiol by CYP1A1, CYP1A2 and CYP3A4 or into 4-hydroxyoestradiol by CYP1B1. The catechol metabolite is O-methylated by catechol O-methyltransferase (COMT), alternatively they can be oxidized into semiquinone and quinone generating free radicals. 1 Reported or expected enzyme expression or activity of the minor allele protein relative to the major allele.
The majority of the hospital controls were admitted at Department of Orthopaedic Surgery, and others were admitted at Department of Gynaecology and Obstetrics and diagnosed with non-malignant abnormalities in uterus, ovaries and breast, including cysts, metrorrhagia, menorrhagia and cystocele.
Controls and cases were matched on age and residential region; however, the matching was not fully successful, and cases were slightly older than controls (table 1) . We did not follow up on the participants after inclusion in the study. All subjects were of Greenlandic Inuit descent, defined as being born and having more than two grandparents born in Greenland. Blood samples were taken when breast cancer was diagnosed and before any treatment was initiated. All participants gave written informed consent before participation.
Information on demographic and lifestyle parameters was obtained by questionnaires.
DNA isolation and genotyping. We used the Human Genome Variation Society (HGVS) recommendations [29] to describe the genetic variations analysed, on coding DNA level c.1 refers to the first nucleotide of the translation start codon and on protein level p.1 refers to the first amino acid of the protein sequence.
DNA isolation and genotyping were performed as previously described [9] . Genomic DNA was extracted from whole blood using the QIAamp DNA MINI Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. We analysed the following [5] ]. The BRCA1 Cys39Gly genotype was obtained from hospital records or if not available using allele-specific PCR amplification. The BRCA1 Cys39Gly genotype was found in the hospital records for 38% of the participants (mainly cases), and the remaining samples were analysed as previously described [9] . Six samples (both non-carriers and carriers) with information from the hospital records were analysed again in parallel using allele-specific PCR amplification, to ensure that identical results were obtained using the different methods. Only samples from 2011 to 2014 were analysed for BRCA1 4684delCC mutation, as DNA was not available for the 2000-2003 samples, using PCR amplification with subsequent restriction enzyme digest. PCR amplification was carried out in a 15-lL reaction mixture containing~50 ng DNA, 19 Key Buffer (15 mM MgCl 2 , VWR), 10 nmol forward 
, hexachlorobenzene (HCB), cisand trans-nonachlor, and oxychlordane] were measured by gas chromatography-mass spectrometry at Le Centre de Toxicologie du Qu ebec, Canada. The determined PCBs and OCPs were normalized to the total serum lipid content (given as lg/kg lipid). Ten PFAA [perfluoroheptanoic acid (PFHpA, C7), perfluorooctanoic acid (PFOA, C8), perfluorononanoic acid (PFNA, C9), perfluorodecanoic acid (PFDA, C10), perfluoroundecanoic acid (PFUnA, C11), perfluorododecanoic acid (PFDoA, C12), perfluorotridecanoic acid (PFTrA, C13), perfluorohexane sulphonate (PFHxS, C6), perfluorooctane sulphonate (PFOS, C8) and perflurooctanesulphonamide (PFOSA, C8)] were measured by liquid chromatography-tandem mass spectrometry at Department of Environmental Science, Aarhus University, Denmark. If the serum POP concentration was below limit of detection (LOD), we used LOD/2 as the concentration. Information on POP serum levels was missing for 0.6-1.9% of the samples due to unsuccessful measurement or missing serum samples.
POPs were grouped as follows by summing the concentration: (i) 
Measurement of cotinine.
Plasma level of cotinine was used as a biomarker for current tobacco smoking. The Calbiotech Cotinine Direct ELISA Kit was used to measure the plasma cotinine (Calbiotech Inc., Spring Valley, California, US), and the product protocol was followed. The measurements were carried out on an EL8000 Universal Microplate Reader (Bio-Tek Instruments, Inc, Bad Friedrichshall, Germany).
Measurement of hormone levels in serum. Hormone levels have been associated with breast cancer risk, and the evaluated SNPs may alter hormone levels. We measured serum 17b-oestradiol (E2) and 5a-dihydrotestosterone (DHT) by enzyme-linked immuno-sorbent assay (ELISA) method using Human E2 ELISA kit (Invitrogen, Camarillo, CA, USA) and DHT ELISA kit (Labor Diagnostika Nord, Nordhorn, Germany), respectively, in accordance with the protocols using the EL8000 Universal Microplate Reader (Bio-Tek Instruments, Inc).
Statistical analysis. Differences between groups were analysed using Student's t-test (continuous variables, ln-transformed) or chi-square (v 2 ) test (categorical variables). The distribution of the genotypes was examined for Hardy-Weinberg equilibrium using the chi-square test.
Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CI) for associations between genotypes and breast cancer risk. Associations between genotype and breast cancer risk were tested under codominant (common/common = 0, common/variant = 1, variant/variant = 2) and dominant (common/common = 0, common/variant + variant/variant = 1) allele models, with the homozygous common allele genotype used as reference.
Effect modification was defined as separate POP exposure effects on breast cancer risk according to genotypes of the evaluated SNPs. POP exposures were dichotomized into below or above median, and the dichotomous dominant genotype variables were used. ORs were calculated for each stratum of POP and genotype with 'low POP level and common/common genotype' as reference. Further, ORs for high versus low exposure within genotype strata were calculated. Measures of effect modification were presented on the multiplicative scale and calculated as ratio of ORs (ROR): OR 11 /(OR 01 9 OR 10 ). OR 11 , OR 01 and OR 10 were calculated for women with a high-risk genotype and a high exposure, women with a high exposure alone, women with a high-risk genotype alone, respectively; women with neither a high-risk genotype nor a high exposure were used as the reference group (OR 00 ). Significant effect modification was defined as ROR different from 1. We have previously reported associations between breast cancer risk and POP exposure [25] , where potential confounders (age (continuous), body mass index (BMI) (three groups), cotinine level (continuous), parity (continuous) and breastfeeding history (dichotomous ever)) were considered using the change in estimate approach through backward elimination. The change in estimate between the full logistic model and the model without the variable of interest was calculated. If the change in OR estimate was above 10%, the variable was included in the final model. None of the potential confounders changed the estimate more than 10%; thus, only the unadjusted analyses are reported in the present analyses. The estimates from the models containing all potential confounders were similar to the unadjusted reported estimates. In an additional model, we also included residential region, but this did not change the estimate either.
IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, New York, USA) was used for the statistical analyses. Twosided p-values ≤ 0.050 were considered statistically significant, and p-values ≤ 0.080 were considered as borderline significant. Table 1 presents selected baseline characteristics for cases and controls. Compared with controls, cases were slightly older and had a slightly lower BMI. No other baseline factors showed significant differences between cases and controls.
Results
The distribution of genotypes was consistent with the Hardy-Weinberg equilibrium in both controls and cases, except for CYP1B1 Leu432Val genotype frequencies in cases (not shown). No carriers of the Greenlandic founder mutation BRCA1 4684delCC were detected (among 45 cases and 53 controls); thus, the genetic variation was not included in the further analyses.
Genotype distributions differed by breast cancer status for CYP17A1 -34T>C and BRCA1 Cys39Gly; however, the CYP17A1 -34T>C was only significant in the dominant model (TC + CC versus TT) ( The results for the analyses of effect modification of SNPs on the association between POP exposure and breast cancer risk are shown in tables 3 and 4 and Tables S1-S15. Table 3 summarizes the findings for the summed POP groups: ∑PCB, ∑OCP and ∑PFAA.
For CYP17A1 -34T>C, the effect of POP exposure (PCBs, OCPs and PFAAs) on breast cancer risk tended to be stronger for the homozygous common T allele carriers than for the TC + CC genotype ( (Table S9) .
For CYP1B1 Leu432Val, the effect of POP exposure tended to be stronger in the Leu/Val + Val/Val stratum than in the Leu/Leu stratum (table 3 and Table S10 (Table S15) .
Hormone levels (E2 and DHT) did not differ by genotypes in controls or cases, even though the examined genes are involved in the hormone metabolism (data not shown).
Discussion
In the present study conducted in Greenlandic Inuit women, significant associations between breast cancer risk and the BRCA1 Cys39Gly mutation and the SNP CYP17A1 -34T>C (table 2) were observed. For the present study population, we previously reported associations between breast cancer risk and PFAAs (ΣPFAA, third versus first tertile, OR: 5.29, 95% CI: 2.01; 13.92), PCBs (ΣPCB, third versus first tertile, OR: 2.50, 95% CI: 1.11; 5.63) and OCPs (ΣOCP, third versus first tertile, OR: 1.90, 95% CI: 0.88; 4.07) [25] . In this study, we found significant effect modification of CYP17A1 -34T>C on PFAA exposure (table 4), and tendencies of heterogenic effects of POPs (PCBs, OCPs and PFAAs) were seen across genotype strata (table 3 and  Table S1 -S15). In line with our previous report [25] , positive associations between POP exposure and breast cancer risk were generally seen when analysed within genotype strata.
BRCA1 founder mutations.
In the Greenlandic Inuit population, two BRCA1 founder mutations have been identified [4, 5] -the Cys39Gly and the 4684delCC variations. We observed that the allele frequency of the Gly variant allele of Cys39Gly was significantly associated with breast cancer (table 2). The OR estimate is rather imprecise due to the low Gly allele frequency, especially among the controls. No carriers of the 4684delCC variation were identified, and the variation may be less frequent than the Cys39Gly variation. The Cys39Gly amino acid substitution of a highly conserved cysteine in the RING domain of the BRCA1 protein might damage the function of the protein [30] , and thereby affect breast cancer risk in variant carriers.
Genetic variations in xenobiotic and steroid hormonemetabolizing genes and breast cancer. We observed a significantly lower breast cancer risk for carriers of the C variant allele of CYP17A1 -34T/C, when compared to the TT genotype (table 2), being in line with our previously published study among Greenlandic Inuit [9] . We did not observe any associations between breast cancer risk and the other evaluated SNPs in CYP19A1, CYP1A1, CYP1B1 and COMT (table 2) .
CYP17A1 encodes the CYP17A1 enzyme that mediates 17a-hydroxylase and 17,20-lyase activity and function in the oestrogen/androgen biosynthesis [31] . Substitution of T to C in position -34 of the CYP17A1 gene promoter may increase transcription and expression of the enzyme by creating a Sp-1 binding site [32] . However, in in vitro studies, no binding of Sp-1 recombinant protein to the C variant allele was observed [33] . The effect of the variation, therefore, remains uncertain. The C variant allele in CYP17A1 -34T/C has been associated with increased levels of oestrogens in some studies [34, 35] . In contrast to the significant association observed among Inuit women in the present study, meta-analyses evaluating the effect of the CYP17A1 -34T/C in non-Inuit populations found no associations with breast cancer risk [36, 37] . The allele frequencies for CYP17A1 -34T/C seen in the present study (frequency of T allele, in controls: 0.47 and cases: 0.55, table 2) were similar to what was reported from other ethnic populations (Caucasian, Asian, Hispanic and African American) [37] .
Meta-analyses evaluating the effect of CYP19A1 *19C>T [38] , CYP1A1 Ile462Val [21, 39] , CYP1B1 Leu432Val [40] and COMT Val158Met [11] did, in line with our study, not find any significant associations with breast cancer risk. For CYP19A1 *19C>T and COMT Val158Met, no associations were found overall or when stratifying by ethnicity [11, 38] . However, association between CYP1B1 Val432Leu and breast cancer may vary between different ethnic groups [40] . The meta-analysis found no association between Caucasian and Asian subjects, but a significant inverse association between the common Val allele and breast cancer risk among African Americans or mixed populations was found [40] . The result emphasizes the importance of investigating the associations for genetically different ethnic groups separately. For CYP1A1 Ile462Val, the meta-analysis included 17 studies of different ethnic groups, and no analyses for ethnicity were carried out [21] . Modification of the effect of POP exposure on breast cancer risk by SNPs. Even though not all evaluated SNPs contribute to breast cancer risk independently, combination with exposures to environmental compounds may alter the risk. Significant modification on the effect of PFAA exposure on breast cancer risk by CYP17A1 -34T>C was found (table 4) , and associations between PFAA and breast cancer risk also tended to be heterogeneous across genotypes of the other evaluated SNPs (Tables S3, S6 , S9, S12 and S15). Similarly, tendencies to heterogeneous associations across genotypes were seen for the evaluated SNPs regarding PCB and OCP exposure (table 3) . We have previously reported that serum levels of PCB153 and p,p 0 DDE differed significantly between genotypes of CYP1A1 Ile462Val, CYP1B1 Leu432Val and COMT Val158-Met in Inuit, but not in Europeans [41] . The allele frequencies varied as well between Inuit and Europeans [41] . The enzymes are involved in the detoxification of POPs, and the results indicate that the SNPs can alter the detoxification when exposed to high concentrations of POPs. The modifying effect of CYP1A1 Ile462Val on the association between PCB exposure and breast cancer risk is the most investigated POP gene interaction in relation to breast cancer [9, [17] [18] [19] [20] , and most studies report a significant effect of the variation [17] [18] [19] [20] . We did also observe a tendency to a stronger association between OCP/PCB exposure and breast cancer risk in the Ile/Val + Val/Val strata, but the effect modification was non-significant.
To our knowledge, there is no report on PFAA metabolism in animals or human beings [42] , but several other mechanisms for modification of the SNPs on the PFAA-related breast cancer risk are biologically possible: 1) PFAAs may inhibit the activity of the CYP enzymes. Narimatsu et al. reported that PFOS inhibited the enzyme activity of nine investigated CYP enzymes [43] ; 2) the CYP enzymes may also be involved in the metabolism of PFAA precursors. CYP2C19 is involved in the oxidative biotransformation of 8:2 fluorotelomer alcohol to PFCAs [44] , and the N-substituted perfluorooctanesulphonamides (PFOSA) are metabolized to PFOS by CYP2A19, CYP3A4 and CYP4A5 in human beings [45] . Other CYP enzymes may be involved in other metabolizing steps or metabolism of other precursors; 3) the PFAAs can alter gene expression of CYP enzymes in several species [46] [47] [48] [49] , and genetic variations may change this effect by either decreasing or increasing the inducible by PFAAs. At this point, these are only hypotheses and need further investigations to clarify the mechanisms.
Limitations.
There are some study limitations to be considered. The sample size is small lowering the statistical power. A sufficient power is especially lacking in the analyses of modification effects, but studies of these in the Greenlandic Inuit are important because of their extreme high POP exposure [50, 51] and they may differ from other populations regarding SNP allele frequencies [41] . Due to the low statistical power to identify gene-environment interaction, the findings are exploratory and may be hypothesis-generating for future larger studies.
Some of the significant results in the present study may be due to chance findings, considering the high number of tests. However, the biologically plausible mechanisms and previous epidemiological evidence support modification of genotypes on the association between environmental exposures and breast cancer risk. We did not adjust statistically for multiple testing, as the measured levels of POP were highly correlated. However, with the a-level of 0.05, we would expect only 5% of the tests to be significant by chance (false positives), but for the analyses of modifications of PFAA effects by CYP17A1, 30% of the tests were significant (table 3). Confounding by population stratification may be one of the main confounding concerns in genetic case-control studies. Bias may be caused by genotypic differences between cases and controls, not associated with diseases risk but generated because of different population origin [52] . To overcome this problem, we included only Greenlandic Inuit women expected to be genetically homogenous. We found that CYP1B1 Leu432Val was not in Hardy-Weinberg equilibrium among the cases. We did not observe an independent association with breast cancer for this SNP, but other studies found that one of the major causes of deviation from Hardy-Weinberg equilibrium was association with disease [53] . Even though deviation from the Hardy-Weinberg equilibrium can indicate genotyping error, we do not see any reason to assume that this is the case with CYP1B1 Leu432Val.
We examined the influences of the SNP in phase I and phase II genes individually, and the balance between the two gene phases (toxication and detoxification) determines the concentration of reactive species. Combinations of several genetic variations in the genes may have a stronger impact than the individual variations [54] . Larger studies, including analyses of SNP combinations, may be important to elucidate the full effect of gene-environment interaction in relation to breast cancer as well as other diseases.
As expected, the BRCA1 Cys39Gly variation was significantly associated with increased breast cancer risk. Significant effect modification of CYP17A1 -34T>C on the exposure effects of ∑PFAA, ∑PFSA and PFOS was seen, and non- N, ca/co, number of cases and controls; PFAA, perfluoroalkyl acids; PFDA, perfluorodecanoic acid; PFDoA, perfluorododecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxS, perfluorohexane sulphonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulphonate; PFOSA, perflurooctanesulphonamide; PFTrA, perfluorotridecanoic acid; PFUnA, perfluoroundecanoic acid; OR, odds ratio; 95% CI, 95% confidence interval; ROR, ratio of odds ratios, from the analyses using the dominant genotype model and dichotomous exposure variables (below or above median). Only unadjusted analyses are reported, as none of the potential confounders (age, body mass index, cotinine levels, parity and breastfeeding) changed the estimate more than 10% (see methods for more details). No correction for multiple testing was carried out due to the strong correlation between the exposure variables. significant heterogeneous effects of PCB, OCP and PFAA exposures in relation to breast cancer were generally seen across genotype strata of the evaluated SNPs. These results indicate that genetic variations, especially CYP17A1 -34T>C, but also CYP19A1 *19C>T, CYP1A1 Ile462Val, CYP1B Leu432Val and COMT Val158Met, can modify the effect of POP exposure on breast cancer risk. Furthermore, the Inuit women being carriers of the common CYP17A1 T allele had a higher risk of breast cancer in accordance with the higher PFAA susceptibility seen in TT carriers compared to carriers of the C variant.
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